New Tools For Cancer Diagnostics: Circulating Tumor Cells and Novel Molecular Targets
New Tools For Cancer Diagnostics: Circulating Tumor Cells and Novel Molecular Targets
Automated Methods for decoding cell morphology from microscopy images with applications to pathology and cytology.
High-precision H&E image segmentation and new mathematical and statistical data analysis methods can be used to automatically differentiate and grade malignancies based on nuclear structure (size, shape, chromatin distribution, as well as other cellular organelles and stains).
Molecular Beacons a method for a quick, high-sensitive allele-specific mutation and RNA
expression analyses. It can be combined with DNA FISH to simultaneously detect DNA Copy Number Variations (CNV), gene rearrangements and RNA expression.
Control
SKBR3 Breast Cancer Cells in donor blood (500 cells in 5ml whole peripheral blood healthy donor)
ALK BA FISH
UroVysion FISH
negative
Isolation of CTCs by size exclusion from patient peripheral blood by CellSieve TM microfilters with dense, uniform 8m pores.
H&E Class C
DCIS
Classification results
For alpha = 0.0025 (visualizations next slide) Predicted Class C vs. Class D Class C Class D Class C 11 0 Actual Class D 0 8 Accuracy 100%
The new methods can be effective in automatically uncovering hidden and visually interpretable differences in cell morphology between disease states. These methods could be used to grade malignancies based on nuclear structure as well as other cellular organelles and stains.
Research Implications
Characterization of CTC
Non-invasive fast and effective method for assessment of metastatic disease Finding best assay for characterization of isolated CTC DNA FISH (gene rearrangements, deletions, amplifications-tumor fingerprinting); PCR, sequencing mutation analysis RNA ViewRNA (Affymetrix), Molecular Beacons for gene expression Protein immunohistochemistry, mass-spectrometry
Future Direction
Clinical Application
Development of clinical assay for detection of CTCs New diagnostics development that combine DNA and RNA analyses
Basic Research
Production of patient-specific metastatic tumors from CTCs in mice (Xenograft assay) Therapeutic Target/Drug validation on xenografts
What are the current challenges & obstacles? Availability of the clinical material acquired through NIH protocol
(identify barriers and limitations beyond time, money, people, travel, and space)
Collaborators
Laboratory of Pathology - CCR
Frederic Barr, M.D., Ph.D. Stephen Hewitt, M.D., Ph.D. Elaine Jaffe, M.D. Maria Merino, M.D. Markku Miettinen, M.D. Carl Oberholtzer, M.D., Ph.D. Martha Quezado, M.D. Mark Raffeld, M.D. Maria Tsokos, M.D.
Georgetown University
Giuseppe Giaccone, MD
NCI, CCR
Udayan Guha, Medical Oncology Branch, CCR Marston Linehan, Urologic Oncology Branch, CCR Lauren Wood, Vaccine Branch, CCR Alexander Gorbach, Ph.D.
NIBIB